T/F? Bone density is recommended in all women 2 years post-menopause. - (correct Answer) - FALSE
-Baseline 65years and older
A 52-year-old woman presents with amenorrhea for one year and moderate hot flashes for 6 months.
She is interested in bioidentical hormone relief for her hot flashes and wants to know if they are better
for her than other hormones. Appropriate info to provide would be, what? - (correct Answer) - 17 beta-
estradiol is a bioidentical form of estrogen available in oral, transdermal, and vaginal formulations
Which of the following statements concerning the estrogen agonist/antagonist raloxifine (Evista) is
correct? - (correct Answer) - It is approved for the prevention and treatment of osteoporosis.
T/F? Data supports the use of topically applied progesterone creams for endometrial protection in
menopausal women taking estrogen. - (correct Answer) - FALSE
What would NOT be an expected finding in a pelvic examination of a 70-year-old woman? - (correct
Answer) - Ovaries easily palpable
A menopausal woman experiencing discomfort with sexual intercourse related to vaginal dryness wants
to know whether she should use a vaginal lubricant or a vaginal moisturizer. What would NOT be a true
statement?
a. Lubricants are intended to reduce friction r/t sex
b. Lubricants can take several weeks of use before becoming effective
c. Moisturizers provide long-term relief of vaginal dryness than lubricants
d. Moisturizers are typically applied several times weekly - (correct Answer) - B. Effective immediately
T/F? Data supports the use of hormonal therapy for prevention of cognitive decline if started soon after
menopause. - (correct Answer) - FALSE
An advantage of the transdermal patch over oral delivery of estrogen for women experiencing
menopausal symptoms is that the transdermal delivery method_____________________. - (correct
Answer) - Has less adverse effects on coagulation factors
In one to two years postmenopausal women, you would expect the following hormone level changes
when compared with premenopausal women. - (correct Answer) - Increased FSH, decreased ani-
mullerian hormone, decreased estradiol
The woman who is going to take ospemifene (an estrogen agonist/antagonist) for treatment of
dyspareunia related to vulvovaginal atrophy should be advised that she______________________ -
(correct Answer) - May experience hot flashes as a side effect of this medication